Trial
NCT01646125
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Advanced Non Small Cell Lung Cancer (NSCLC)
Intervention
AUY922
Why stopped
An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-24